CN104144700B - 抗CD1d的抗体 - Google Patents

抗CD1d的抗体 Download PDF

Info

Publication number
CN104144700B
CN104144700B CN201280050432.2A CN201280050432A CN104144700B CN 104144700 B CN104144700 B CN 104144700B CN 201280050432 A CN201280050432 A CN 201280050432A CN 104144700 B CN104144700 B CN 104144700B
Authority
CN
China
Prior art keywords
seq
antibody
antigen
cdld
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280050432.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104144700A (zh
Inventor
J.K.纳姆比亚尔
L.D.波顿
A.克拉克
A.J.波
D.塔姆瓦基斯
G.科普斯达斯
A.G.多伊勒
M.波拉德
H.穆斯塔发
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Cephalon Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904190A external-priority patent/AU2011904190A0/en
Application filed by Cephalon Australia Pty Ltd filed Critical Cephalon Australia Pty Ltd
Publication of CN104144700A publication Critical patent/CN104144700A/zh
Application granted granted Critical
Publication of CN104144700B publication Critical patent/CN104144700B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201280050432.2A 2011-10-14 2012-10-15 抗CD1d的抗体 Expired - Fee Related CN104144700B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161547307P 2011-10-14 2011-10-14
US61/547307 2011-10-14
AU2011904190 2011-10-14
AU2011904190A AU2011904190A0 (en) 2011-10-14 Antibodies to CD1d
PCT/AU2012/001247 WO2013053021A1 (en) 2011-10-14 2012-10-15 ANTIBODIES TO CD1d

Publications (2)

Publication Number Publication Date
CN104144700A CN104144700A (zh) 2014-11-12
CN104144700B true CN104144700B (zh) 2016-10-19

Family

ID=48081279

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280050432.2A Expired - Fee Related CN104144700B (zh) 2011-10-14 2012-10-15 抗CD1d的抗体

Country Status (14)

Country Link
US (1) US20140286957A1 (enExample)
EP (1) EP2766042A4 (enExample)
JP (1) JP2015502915A (enExample)
KR (1) KR20140108520A (enExample)
CN (1) CN104144700B (enExample)
AU (1) AU2012323781B8 (enExample)
BR (1) BR112014008691A2 (enExample)
CA (1) CA2850961A1 (enExample)
EA (1) EA201400447A1 (enExample)
IL (1) IL231975A0 (enExample)
MX (1) MX2014004326A (enExample)
SG (1) SG11201400521PA (enExample)
WO (1) WO2013053021A1 (enExample)
ZA (1) ZA201401776B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201706128PA (en) 2015-01-27 2017-08-30 Lava Therapeutics B V Single domain antibodies targeting cd1d
CN109476724B (zh) * 2016-04-08 2023-04-04 艾达普特免疫有限公司 T细胞受体
DK3440105T3 (da) * 2016-04-08 2022-06-13 Immunocore Ltd T-cellereceptorer
SG11201808751SA (en) * 2016-04-08 2018-11-29 Adaptimmune Ltd T cell receptors
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
AU2018234827B2 (en) * 2017-03-15 2024-04-04 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
BR112021005184A8 (pt) * 2018-09-19 2022-08-16 Lava Therapeutics B V Imunoglobulina cd1d de dupla ação
GB201820006D0 (en) 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
US11725052B2 (en) * 2020-08-18 2023-08-15 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
US20240050569A1 (en) * 2020-12-18 2024-02-15 Bioardis, Llc Mesothelin binding molecules and uses thereof
CN120476137A (zh) 2022-08-18 2025-08-12 英美偌科有限公司 对mage a4具有特异性的t细胞受体融合蛋白
CN116217704B (zh) * 2022-10-25 2025-08-15 南京医科大学 一种抑制肝细胞凋亡的表面分子及其应用
WO2024137789A2 (en) * 2022-12-21 2024-06-27 Board Of Regents, The University Of Texas System Cd3 and itcr expressing engineered natural killer cells with enhanced function for adoptive immunotherapy
WO2024226794A1 (en) * 2023-04-26 2024-10-31 The Trustees Of Indiana University Composition and methods for treatment of spinal cord injury and traumatic brain injury

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002583A1 (en) * 1998-07-09 2000-01-20 Nickoloff, Brian, J. Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US20080254037A1 (en) * 2007-04-12 2008-10-16 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibing nkt cell activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084020B2 (en) * 2002-05-01 2011-12-27 Beth Israel Deaconess Medical Center Use of anti-CD1 antibodies for the modulation of immune responses
WO2008100912A1 (en) * 2007-02-12 2008-08-21 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002583A1 (en) * 1998-07-09 2000-01-20 Nickoloff, Brian, J. Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US20080254037A1 (en) * 2007-04-12 2008-10-16 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibing nkt cell activity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhbition CD1d-dependent NKT cell activation;Lappas CM;《Journal of Experimental Medicine》;20061231;第203卷(第12期);2639-2648 *
CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes;Fais F;《International Journal of Cancer》;20041231;第109卷;402-411 *
Cutting edge: invariant Va14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an Experimental Asthma Model;Lisbonne M;《The journal of Immunology》;20031231;第171卷;1637-1641 *
NKT cells mediate pulmonary inflammation and dysfuncition in murine sickle cell disease through producion of IFN-gamma and CXCR3 chemokines;Wallace KL;《Blood》;20091231;第114卷;667-676 *
Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17;Pichavant M;《Journal of Experimental Medicine》;20081231;第205卷(第2期);385-393 *
The development of airway hyperreactivity in I-bet-deficient mice requires CD1d-restricted NKT cells;Kim HY;《The journal of Immunology》;20091231;第182卷;3252-3262 *

Also Published As

Publication number Publication date
ZA201401776B (en) 2016-01-27
CA2850961A1 (en) 2013-04-18
KR20140108520A (ko) 2014-09-11
US20140286957A1 (en) 2014-09-25
AU2012323781A1 (en) 2014-03-27
BR112014008691A2 (pt) 2017-06-13
EP2766042A1 (en) 2014-08-20
CN104144700A (zh) 2014-11-12
EA201400447A1 (ru) 2014-09-30
IL231975A0 (en) 2014-05-28
AU2012323781B8 (en) 2015-05-14
SG11201400521PA (en) 2014-08-28
AU2012323781B2 (en) 2015-04-23
NZ622050A (en) 2016-07-29
WO2013053021A1 (en) 2013-04-18
AU2012323781A8 (en) 2015-05-14
JP2015502915A (ja) 2015-01-29
EP2766042A4 (en) 2015-05-27
MX2014004326A (es) 2014-09-25

Similar Documents

Publication Publication Date Title
CN104144700B (zh) 抗CD1d的抗体
US12410256B2 (en) Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases
US20220380458A1 (en) Binding molecules specific for fcgamma riia and uses thereof
AU2010270241B2 (en) Humanised antibodies to Toll-like Receptor 2 and uses thereof
NZ580245A (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
CN112041339A (zh) 用于治疗自身免疫病的抗ifnar1抗体
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
CN105377892A (zh) 抗cd25抗体及其用途
WO2020108611A1 (zh) 抗cd40抗体、其抗原结合片段及其医药用途
TW202003570A (zh) 抗trem-1抗體及其用途
CN105121470A (zh) 抗cd25抗体及其用途
US20210269520A1 (en) Anti-human cd19 antibodies
KR20230078657A (ko) 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물
KR102862077B1 (ko) 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
EP4073117A1 (en) New antibody blocking human fcgriiia and fcgriiib
TW202336035A (zh) 治療自體免疫疾病及癌症之方法及組成物
NZ622050B2 (en) ANTIBODIES TO CD1d
CN119173536A (zh) 抗cd94抗体和其使用方法
NZ622092A (en) Antibodies against tl1a and uses thereof
NZ622092B2 (en) Antibodies against tl1a and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161019

Termination date: 20171015

CF01 Termination of patent right due to non-payment of annual fee